Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study

Background Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, a cornerstone cytokine in psoriasis, has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations. Objectives To report the long-term (2 center dot 5-year) efficacy and safety of secukinumab in nail psoriasis. Methods TRANSFIGURE, a double-blind, randomized, placebo-controlled, parallel-group, multicentre phase IIIb study in 198 patients, investigated secukinumab 150 mg and 300 mg in patients with moderate-to-severe nail psoriasis. Results At week 16, the primary endpoint Nail Psoriasis Severity Index (NAPSI) was met, demonstrating superiority of secukinumab to placebo. The effect was sustained over 2 center dot 5 years with a large benefit for nail clearance, with mean NAPSI improvement of -73 center dot 3% and -63 center dot 6% with secukinumab 300 mg and 150 mg, respectively. At 2 center dot 5 years, secukinumab demonstrated sustained clinically significant reductions in total mean Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) quality-of-life (QoL) scores of -52 center dot 4% and -18 center dot 1%, and 70% and 71% of patients achieved a weighted NAPPA Patient Benefit Index global score of >= 2 with secukinumab 300 mg and 150 mg, respectively. Patients showed considerable improvements in the EuroQol 5-Dimension health status questionnaire at 2 center dot 5 years, reporting a decrease in pain and discomfort. No new safety findings were observed. Conclusions Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2 center dot 5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile.

Automated summary

Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2 center dot 5 years in nail psoriasis, with significant sustained quality-of-life improvements and a favorable safety profile. No new safety findings were observed, indicating the long-term safety of Secukinumab in treating nail psoriasis.